# Bevacizumab Plus mFOLFOXIRI as First-line Treatment for Patients With Unresectable Metastatic Colorectal Cancer

Source: https://onco.cc/trials/nct04230187/  
OnCo record `nct04230187` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial in colorectal cancer, run by Yanhong Deng, active but no longer recruiting.

## Summary

Bevacizumab Plus mFOLFOXIRI as First-line Treatment for Patients With Unresectable Metastatic Colorectal Cancer is a phase 3, randomised interventional study registered as NCT04230187 by Yanhong Deng, with a registry enrolment figure of 528 participants, started 2020-09-01 and due to reach its primary completion in 2026-09-01. Interventions recorded: mFOLFOXIRI plus Bevacizumab; mFOLFOX6 Plus Bevacizumab. Conditions listed: Colorectal Cancer. Primary outcome: Progression-free survival (PFS). Colorectal eligibility wording from the registry: "\- Histological or cytological documentation of adenocarcinoma of the colon or rectum". Sites: China. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-24
- Also known as: TRIBE-C
- Tags: ctgov-ingest; colorectal-deep-dive
- Registry id: NCT04230187
- Phase: 3
- Setting: Bevacizumab Plus mFOLFOXIRI or mFOLFOX-6 as First-line Treatment for Patients With Unresectable Metastatic Colorectal Cancer: a Randomised, Open-label, Phase 3 Trial
- Sponsor: Yanhong Deng
- Enrolled: 528

## Sources

- ClinicalTrials.gov NCT04230187: https://clinicaltrials.gov/study/NCT04230187

## Connected records

- cancers: [Colon cancer (adenocarcinoma of the colon)](https://onco.cc/cancers/colon-cancer/), [Rectal cancer](https://onco.cc/cancers/rectal-cancer/)
- terms: [Colorectal cancer trials open today (registry snapshot)](https://onco.cc/terms/colorectal-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct04230187.json